Xencor, Inc. (XNCR) is a publicly traded Healthcare sector company. As of July 8, 2026, XNCR trades at $15.67 with a market cap of $1.10B and a P/E ratio of -6.72. XNCR moved +5.31% today. Year to date, XNCR is +4.26%; over the trailing twelve months it is +97.36%. Its 52-week range spans $6.92 to $27.24. Analyst consensus is strong buy with an average price target of $24.30. Rallies surfaces XNCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GT Biopharma Uses AI to Fast-Track Pre-IND Tumor-Targeting Drugs: GT Biopharma has deployed AI-guided sequence and structural analysis across discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, aiming to advance multiple new candidates into pre-IND development by 2027. These efficiency gains coincide with its TriKE platform’s Phase 1 trials, pressuring Xencor’s antibody-engineering pipeline competitiveness.
| Metric | Value |
|---|---|
| Price | $15.67 |
| Market Cap | $1.10B |
| P/E Ratio | -6.72 |
| EPS | $-2.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.24 |
| 52-Week Low | $6.92 |
| Volume | 591.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $97.36M |
| Net Income | $-172.42M |
| Gross Margin | 0.00% |
11 analysts cover XNCR: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.30.